SCHEMBL5029480

SCHEMBL5029480

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 13/20 0.73
BCR P11274 13/20 0.73
CSF1R P07333 1/20 0.66
PDGFRB P09619 3/20 0.63
HDAC1 Q13547 3/20 0.63
HDAC2 Q92769 3/20 0.63
MAPK1 P28482 3/20 0.63
DDR1 Q08345 3/20 0.63
DDR2 Q16832 3/20 0.63
ESYT2 A0FGR8 2/20 0.63
NBAS A2RRP1 2/20 0.63
CNOT1 A5YKK6 2/20 0.63
TBKBP1 A7MCY6 2/20 0.63
AGPS O00116 2/20 0.63
MYO1F O00160 2/20 0.63
SNAP23 O00161 2/20 0.63
AP3B1 O00203 2/20 0.63
PSMD12 O00232 2/20 0.63
BMPR1B O00238 2/20 0.63
PGRMC1 O00264 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715868 0.93 ABL1 (0.69) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL5023657 0.93 ABL1 (0.80) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL5023651 0.92 POLB (0.68) ABL1BCRCSF1RMAPK1DDR1
SCHEMBL5027553 0.90 ABL1 (0.70) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL5025205 0.89 ABL1 (0.70) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL14286283 0.88 ABL1 (0.71) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL716834 0.88 ABL1 (0.69) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL14286284 0.87 ABL1 (0.68) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL5025921 0.86 ABL1 (0.64) ABL1BCRCSF1RPDGFRBHDAC1
SCHEMBL5025920 0.85 ABL1 (0.67) ABL1BCRCSF1RPDGFRBHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US claimed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN claimed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP claimed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO claimed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN disclosed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP disclosed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors KIT, MAP3K2, RET ABL1 22/4885BCR 349/4885CSF1R 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.